The FDA said yesterday that after two years, there is no longer a shortage of injection products for semaglutide, the key ingredient in Novo Nordisk A/S’s blockbuster weight loss and diabetes drugs. The announcement means the countdown has begun for companies like Hims & Hers to either stop making their cheaper, compounded versions or, much more likely,…
